Top

BMC Pulmonary Medicine

Published in:

Open Access 01-12-2016 | Case report

Successful treatment of severe Pneumocystis pneumonia in an immunosuppressed patient using caspofungin combined with clindamycin: a case report and literature review

Authors: Hongjuan Li, Haoming Huang, Hangyong He

Published in: BMC Pulmonary Medicine | Issue 1/2016

Abstract

Background

Pneumocystis jirovecii is responsible for Pneumocystis pneumonia (PCP), which occurs almost exclusively in immunocompromised individuals. Trimethoprim-sulfamethoxazole (TMP-SMZ) is regarded as the first-line treatment and prophylaxis for P. jirovecii infection, but the frequency of adverse reactions and newly emerged antibiotic resistance limit its use.

Case presentation

Ulcerations and hemorrhages involving the tongue were noted secondary to TMP-SMZ desensitization against PCP in a 46-year-old male who had previously been diagnosed with IgA nephropathy and sustained prolonged corticosteroid therapy. There was an urgent need for an alternative regimen due to the severe response to TMP-SMZ. The patient was successfully treated with a combination therapy of caspofungin and clindamycin.

Conclusion

Caspofungin combined with clindamycin is an optional treatment for PCP when treatment with TMP-SMZ fails or in patients who cannot tolerate TMP-SMZ.

Ye W-L, Tang N, Wen Y-B, Li H, Li M-X, Bin D, Li X-M. Underlying renal insufficiency: the pivotal risk factor for Pneumocystis jirovecii pneumonia in immunosuppressed patients with non-transplant glomerular disease. Int Urol Nephrol. 2016. doi:10.1007/s11255-016-1324-x.

Boonsarngsuk V, Sirilak S, Kiatboonsri S. Acute respiratory failure due to Pneumocystis pneumonia: outcome and prognostic factors. Int J Infect Dis. 2008;13:59–66.CrossRefPubMed

Li M-C, Lee N-Y, Lee C-C, Lee H-C, Chang C-M, Ko W-C. Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect. 2012;47:42–7.CrossRefPubMed

Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1–198.

Sun P, Tong Z. Efficacy of caspofungin, a 1,3-β-D-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats. Med Mycol. 2014;52:798–803.CrossRefPubMed

Lobo ML, Esteves F, de Sousa B, Cardoso F, Cushion MT, Antunes F, Matos O. Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for Pneumocystis pneumonia: a pilot study in mice. PLoS ONE. 2013;8:e70619.CrossRefPubMedPubMedCentral

Cushion MT, Linke MJ, Ashbaugh A, Sesterhenn T, Collins MS, Lynch K, Brubaker R, Walzer PD. Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS ONE. 2010;5:e8524.CrossRefPubMedPubMedCentral

Wyder MA, Rasch EM, Kaneshiro ES. Quantitation of absolute Pneumocystis carinii nuclear DNA content. Trophic and cystic forms isolated from infected rat lungs are haploid organisms. J Eukaryot Microbiol. 1998;45:233–9.CrossRefPubMed

Nollstadt KH, Powles MA, Fujioka H, Aikawa M, Schmatz DM. Use of beta-1,3-glucan-specific antibody to study the cyst wall of Pneumocystis carinii and effects of pneumocandin B0 analog L-733,560. Antimicrob Agents Chemother. 1994;38:2258–65.CrossRefPubMedPubMedCentral

10.

Chou C-W, Chao H-S, Lin F-C, Tsai H-C, Yuan W-H, Chang S-C. Clinical usefulness of HRCT in assessing the severity of Pneumocystis jirovecii Pneumonia: a cross-sectional study. Medicine. 2015;94:e768.CrossRefPubMedPubMedCentral

11.

Vogel MN, Vatlach M, Weissgerber P, Goeppert B, Claussen CD, Hetzel J, Horger M. HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients. Eur J Radiol. 2011;81:1315–20.CrossRefPubMed

12.

Sasso M, Chastang-Dumas E, Bastide S, Alonso S, Lechiche C, Bourgeois N, Lachaud L. Performances of four real-time PCR assays for diagnosis of Pneumocystis jirovecii pneumonia. J Clin Microbiol. 2015;54:625–30.CrossRefPubMed

13.

Hauser PM, Bille J, Lass-Flörl C, Geltner C, Feldmesser M, Levi M, Patel H, Muggia V, Alexander B, Hughes M, Follett SA, Cui X, Leung F, Morgan G, Moody A, Perlin DS, Denning DW. Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay. J Clin Microbiol. 2011;49:1872–8.CrossRefPubMedPubMedCentral

14.

Held J, Koch MS, Reischl U, Danner T, Serr A. Serum (1 → 3)-β-D-glucan measurement as an early indicator of Pneumocystis jirovecii pneumonia and evaluation of its prognostic value. Clin Microbiol Infect. 2010;17:595–602.CrossRef

15.

Li W-J, Guo Y-L, Liu T-J, Wang K, Kong J-L. Diagnosis of pneumocystis pneumonia using serum (1–3)-β-D-Glucan: a bivariate meta-analysis and systematic review. J Thorac Dis. 2015;7:2214–25.PubMedPubMedCentral

16.

Kamada T, Furuta K, Tomioka H. Pneumocystis pneumonia associated with human immunodeficiency virus infection without elevated (1 → 3)-β-D glucan: A case report. Respir Med Case Rep. 2016;18:73–5.PubMedPubMedCentral

17.

Phair J, Muñoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990;322:161–5.CrossRefPubMed

18.

Avino LJ, Naylor SM, Roecker AM. Pneumocystis jirovecii pneumonia in the non-HIV-infected population. Ann Pharmacother. 2016;50:673–9.CrossRefPubMed

19.

Moukhlis R, Boyer J, Lacube P, Bolognini J, Roux P, Hennequin C. Linking Pneumocystis jiroveci sulfamethoxazole resistance to the alleles of the DHPS gene using functional complementation in Saccharomyces cerevisiae. Clin Microbiol Infect. 2009;16:501–7.CrossRefPubMed

20.

Queener SF, Cody V, Pace J, Torkelson P, Gangjee A. Trimethoprim resistance of dihydrofolate reductase variants from clinical isolates of Pneumocystis jirovecii. Antimicrob Agents Chemother. 2013;57:4990–8.CrossRefPubMedPubMedCentral

21.

Xinqiang L. An analysis of adverse reactions induced by compound sulfamethoxazole tablets in 267 cases. Chin J Pharmaco Epidemiol. 2004;13:139–40.

22.

Borchani C, Fonteyn F, Jamin G, Destain J, Willems L, Paquot M, Blecker C, Thonart P. Structural characterization, technological functionality, and physiological aspects of fungal β-D-glucans: a review. Crit Rev Food Sci Nutr. 2015;56:1746–52.CrossRef

23.

Vassallo R, Standing JE, Limper AH. Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol. 2000;164:3755–63.CrossRefPubMed

24.

Utili R, Durante-Mangoni E, Basilico C, Mattei A, Ragone E, Grossi P. Efficacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe Pneumocystis pneumonia in solid organ transplant recipients. Transplantation. 2007;84:685–8.CrossRefPubMed

25.

Armstrong-James D, Stebbing J, John L, Murungi A, Bower M, Gazzard B, Nelson M. A trial of caspofungin salvage treatment in PCP pneumonia. Thorax. 2011;66:537–8.CrossRefPubMed

26.

Fichera M, Roos D. A plastid organelle as a drug target in apicomplexan parasites. Nature. 1997;390:407–9.CrossRefPubMed

27.

Seaberg LS, Parquette AR, Gluzman IY, Phillips GW, Brodasky TF, Krogstad DJ. Clindamycin activity against chloroquine-resistant Plasmodium falciparum. J Infect Dis. 1984;150:904–11.CrossRefPubMed

28.

Vale N, Moreira R, Gomes P. Primaquine revisited six decades after its discovery. Eur J Med Chem. 2009;44:937–53.CrossRefPubMed

29.

Queener SF, Bartlett MS, Richardson JD, Durkin MM, Jay MA, Smith JW. Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother. 1988;32:807–13.CrossRefPubMedPubMedCentral

30.

Toma E, Thorne A, Singer J, Raboud J, Lemieux C, Trottier S, Bergeron MG, Tsoukas C, Falutz J, Lalonde R, Gaudreau C, Therrien R. Clindamycin with primaquine vs. Trimethoprim-sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial (CTN 004). CTN-PCP Study Group. Clin Infect Dis. 1998;27:524–30.CrossRefPubMed

31.

Smego J, Nagar S, Maloba B, Popara M. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch Intern Med. 2001;161:1529–33.CrossRefPubMed

32.

Zhang Y, Zhang H, Xu J, Wu C, Ma X. Lack of response in severe pneumocystis pneumonia to combined caspofungin and clindamycin treatment: a case report. Chin Med Sci J. 2011;26:246–8.CrossRef

33.

Chou C-W, Lin F-C, Tsai H-C, Chang S-C. The impact of concomitant pulmonary infection on immune dysregulation in Pneumocystis jirovecii pneumonia. BMC Pulm Med. 2014;14:182.CrossRefPubMedPubMedCentral

Title: Successful treatment of severe Pneumocystis pneumonia in an immunosuppressed patient using caspofungin combined with clindamycin: a case report and literature review
Authors: Hongjuan Li
Haoming Huang
Hangyong He
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Pulmonary Medicine / Issue 1/2016
Electronic ISSN: 1471-2466
DOI: https://doi.org/10.1186/s12890-016-0307-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Successful treatment of severe Pneumocystis pneumonia in an immunosuppressed patient using caspofungin combined with clindamycin: a case report and literature review

Abstract

Background

Case presentation

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2016

Immediate effect of CPAP titration on perceived health related quality of life: a prospective observational study

Transient symptomatic hyperglycaemia secondary to inhaled fluticasone propionate in a young child

Adiposity influences airway wall thickness and the asthma phenotype of HIV-associated obstructive lung disease: a cross-sectional study

Mean pulmonary arterial pressure as a prognostic indicator in connective tissue disease associated with interstitial lung disease: a retrospective cohort study

Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study

Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page